The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy DOI
Vishnu Murthy,

Vinícius Ludwig,

Andrei Gafita

et al.

Journal of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown, P. jnumed.124.268818 - jnumed.124.268818

Published: Feb. 27, 2025

Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). 177Lu PSMA-targeted radiopharmaceutical therapy (RPT) enables direct delivery β-radiation to PSMA-expressing PCa cells while minimizing damage normal tissue. As PSMA RPT becomes more widely used, there growing interest in evaluating predictive prognostic role parameters enable better patient selection effectively monitor treatment response. The purpose this paper review as biomarkers RPT. Quantitative on baseline can serve overall survival prostate-specific Alongside lesion-based assessments, changes whole-body quantitative from interim or end-of-treatment are progression-free patients undergoing Changes quantitative, may reflect following systemic compared with individual assessments. Further research necessary larger, prospective trials characterize metastatic castration-resistant

Language: Английский

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy DOI
Vishnu Murthy,

Vinícius Ludwig,

Andrei Gafita

et al.

Journal of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown, P. jnumed.124.268818 - jnumed.124.268818

Published: Feb. 27, 2025

Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). 177Lu PSMA-targeted radiopharmaceutical therapy (RPT) enables direct delivery β-radiation to PSMA-expressing PCa cells while minimizing damage normal tissue. As PSMA RPT becomes more widely used, there growing interest in evaluating predictive prognostic role parameters enable better patient selection effectively monitor treatment response. The purpose this paper review as biomarkers RPT. Quantitative on baseline can serve overall survival prostate-specific Alongside lesion-based assessments, changes whole-body quantitative from interim or end-of-treatment are progression-free patients undergoing Changes quantitative, may reflect following systemic compared with individual assessments. Further research necessary larger, prospective trials characterize metastatic castration-resistant

Language: Английский

Citations

0